Back
Summit Therapeutics 10K Form
Sell
31
SMMT
Summit Therapeutics
Last Price:
$17.89
Seasonality Move:
18.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-07 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2023-08-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2023-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-11-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-08-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
Receive SMMT News And Ratings
See the #1 stock for the next 7 days that we like better than SMMT
SMMT Financial Statistics
Sales & Book Value
| Annual Sales: | $705K |
|---|---|
| Cash Flow: | $-30.4M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.59 |
| Price / Book: | 30.09 |
Profitability
| EPS (TTM): | -0.24000 |
|---|---|
| Net Income (TTM): | $-196.7M |
| Gross Margin: | $760K |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Summit Therapeutics Earnings Forecast
Key Summit Therapeutics Financial Ratios
-
The Gross Profit Margin over the past 15 years for SMMT is 102.29%.
-
The Selling, General & Administrative Expenses for SMMT have been equal to 3,787.23% of Gross Profit Margin.
-
The Interest Expense is -2.68% of Operating Income.
-
Per Share Earnings over the last 19 years have been positive in 8 years.
Summit Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | SMMT |
| CUSIP: | 86627R |
| Website: | smmttx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
SMMT Technical Analysis vs Fundamental Analysis
Sell
31
Summit Therapeutics (SMMT)
is a Sell
Is Summit Therapeutics a Buy or a Sell?
-
Summit Therapeutics stock is rated a SellThe current Summit Therapeutics [SMMT] share price is $17.87. The Score for SMMT is 31, which is 38% below its historic median score of 50, and infers higher risk than normal.